Wall Street analysts forecast that Exelixis, Inc. (NASDAQ:EXEL) will report earnings per share (EPS) of $0.13 for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Exelixis’ earnings, with estimates ranging from $0.07 to $0.19. Exelixis posted earnings per share of $0.37 in the same quarter last year, which indicates a negative year-over-year growth rate of 64.9%. The business is expected to report its next earnings results on Tuesday, February 11th.
On average, analysts expect that Exelixis will report full year earnings of $0.97 per share for the current fiscal year, with EPS estimates ranging from $0.92 to $1.06. For the next financial year, analysts expect that the company will report earnings of $0.88 per share, with EPS estimates ranging from $0.67 to $1.02. Zacks’ earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Exelixis.
Exelixis (NASDAQ:EXEL) last posted its earnings results on Wednesday, October 30th. The biotechnology company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.12. Exelixis had a net margin of 64.05% and a return on equity of 25.55%. The company had revenue of $271.70 million for the quarter, compared to analyst estimates of $228.17 million. During the same period in the previous year, the business posted $0.44 EPS. Exelixis’s revenue was up 20.5% on a year-over-year basis.
Shares of NASDAQ EXEL traded up $0.21 during midday trading on Friday, reaching $17.36. 3,189,564 shares of the stock were exchanged, compared to its average volume of 2,633,126. The company has a 50 day simple moving average of $16.49 and a 200 day simple moving average of $19.08. The stock has a market capitalization of $5.21 billion, a P/E ratio of 12.14, a PEG ratio of 2.26 and a beta of 1.78. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.80 and a current ratio of 6.89. Exelixis has a twelve month low of $15.02 and a twelve month high of $25.31.
In other news, CEO Michael Morrissey sold 37,227 shares of the firm’s stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $19.20, for a total transaction of $714,758.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CMO Gisela Schwab sold 50,000 shares of the firm’s stock in a transaction on Monday, November 4th. The stock was sold at an average price of $15.99, for a total value of $799,500.00. The disclosure for this sale can be found here. Insiders sold a total of 194,894 shares of company stock worth $3,407,716 over the last three months. Insiders own 4.50% of the company’s stock.
Hedge funds have recently bought and sold shares of the stock. Financial Gravity Wealth Inc. boosted its holdings in Exelixis by 120,100.0% during the 2nd quarter. Financial Gravity Wealth Inc. now owns 1,202 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 1,201 shares during the period. Bessemer Group Inc. acquired a new position in Exelixis in the 2nd quarter valued at about $28,000. Ibex Wealth Advisors purchased a new stake in Exelixis during the second quarter worth about $43,000. Signaturefd LLC increased its stake in Exelixis by 999.5% during the second quarter. Signaturefd LLC now owns 2,287 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 2,079 shares during the period. Finally, Point72 Hong Kong Ltd lifted its position in shares of Exelixis by 75.0% during the second quarter. Point72 Hong Kong Ltd now owns 2,411 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 1,033 shares in the last quarter. Hedge funds and other institutional investors own 77.03% of the company’s stock.
Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
Featured Article: What is the CAC 40 Index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.